BRAF and metastatic melanoma: Differently from the treatment of the metastatic melanoma, where the ratio between risks and benefits of immunotherapy with ICI is in favor of the benefits, at least in the presence of BRAF wildtype tumors, the same risks/benefits balance could be completely altered in the adjuvant setting.